# A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

Study · id `cardio:ct-nct06926660` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06926660](<https://clinicaltrials.gov/study/NCT06926660>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06926660

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 492 participants.

## Technical summary

Registry record NCT06926660. Randomized; quadruple masking; primary purpose treatment. Start 2025-07-18 (actual); primary completion 2026-08-14 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 492 participants (enrolled count; ClinicalTrials.gov record NCT06926660, source copy `cardio:ctgov-nct06926660-2026-09-30`, retrieved 2026-10-26)
- Started: 2025-07-18 (actual) (ClinicalTrials.gov record NCT06926660, source copy `cardio:ctgov-nct06926660-2026-09-30`, retrieved 2026-10-26)
- Primary completion: 2026-08-14 (actual) (ClinicalTrials.gov record NCT06926660, source copy `cardio:ctgov-nct06926660-2026-09-30`, retrieved 2026-10-26)
- Completion: 2026-08-14 (actual) (ClinicalTrials.gov record NCT06926660, source copy `cardio:ctgov-nct06926660-2026-09-30`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Belgium; Brazil; Canada; China; Czechia; France; Germany; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Philippines; Poland; Puerto Rico; South Korea; Spain; Taiwan; Thailand; United Kingdom (ClinicalTrials.gov record NCT06926660, source copy `cardio:ctgov-nct06926660-2026-09-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06926660-2026-09-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
- Condition: Chronic Kidney Disease
- Intervention (Drug): Vicadrostat
- Intervention (Drug): Empagliflozin
- Intervention (Drug): Placebo matching vicadrostat
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)

## Provenance

Content hash: 57beea4d66fe6d580af3de78f6e0e3c74d74d2ef0a318c1b75471a91706b06cf
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
